Your browser is no longer supported. Please, upgrade your browser.
Settings
HTBX Heat Biologics, Inc. daily Stock Chart
HTBX [NASD]
Heat Biologics, Inc.
Index- P/E- EPS (ttm)-0.54 Insider Own5.30% Shs Outstand57.28M Perf Week57.60%
Market Cap71.50M Forward P/E- EPS next Y-0.32 Insider Trans0.00% Shs Float74.59M Perf Month74.69%
Income-20.60M PEG- EPS next Q-0.08 Inst Own19.30% Short Float1.73% Perf Quarter303.18%
Sales3.20M P/S22.34 EPS this Y33.20% Inst Trans- Short Ratio0.08 Perf Half Y104.23%
Book/sh0.47 P/B2.02 EPS next Y-2.90% ROA-69.90% Target Price- Perf Year28.42%
Cash/sh0.35 P/C2.71 EPS next 5Y- ROE-103.60% 52W Range0.19 - 1.25 Perf YTD100.06%
Dividend- P/FCF- EPS past 5Y49.50% ROI-151.80% 52W High-23.98% Beta-0.08
Dividend %- Quick Ratio3.90 Sales past 5Y- Gross Margin- 52W Low387.33% ATR0.08
Employees36 Current Ratio3.90 Sales Q/Q28.60% Oper. Margin- RSI (14)81.93 Volatility18.94% 10.74%
OptionableNo Debt/Eq0.01 EPS Q/Q36.10% Profit Margin- Rel Volume1.61 Prev Close0.95
ShortableYes LT Debt/Eq0.01 EarningsMay 27 BMO Payout- Avg Volume16.41M Price0.95
Recom2.00 SMA2051.00% SMA5059.83% SMA20092.84% Volume0 Change0.00%
Jun-20-16Initiated ROTH Capital Buy
Jan-08-16Initiated Noble Financial Buy $16
May-26-15Initiated H.C. Wainwright Buy $13
Sep-18-13Initiated Aegis Capital Buy $36
May-18-20 07:45AM  We're Keeping An Eye On Heat Biologics's (NASDAQ:HTBX) Cash Burn Rate Simply Wall St.
May-15-20 09:30AM  Heat Biologics Provides First Quarter 2020 Business Update ACCESSWIRE
May-14-20 08:00AM  Positive Survival Data from Phase 2 Lung Cancer Trial Accepted for Presentation at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting ACCESSWIRE
May-11-20 08:00AM  Heat Biologics Provides Clinical Update; Reports Continued Progress Advancing HS-110 ACCESSWIRE +5.88%
Apr-29-20 08:37AM  Heat Biologics Reports Progress on COVID-19 Efforts and Timeline of Anticipated Q2 2020 Milestones ACCESSWIRE
Apr-13-20 03:27PM  Coronavirus: Trump retweets call to fire Fauci Yahoo Finance Video +12.04%
Apr-09-20 03:45PM  HTBX: $25M in Cash to Advance Portfolio Zacks Small Cap Research +7.02%
12:57PM  These 20 companies are working on coronavirus treatments or vaccines heres where things stand MarketWatch
Apr-01-20 08:00AM  Heat Biologics Announces Formation of COVID-19 Advisory Board ACCESSWIRE -6.91%
Mar-30-20 08:30AM  Heat Biologics Provides Year-End Business Update ACCESSWIRE
Mar-23-20 02:38PM  Morrisville firm developing coronavirus test that produces results in 30 minutes American City Business Journals
09:00AM  Heat Biologics and University of Miami Developing Proprietary COVID-19 Diagnostic Test Under Collaborative Research Agreement ACCESSWIRE
Mar-17-20 02:35PM  Shares of Heat Biologics rise on plans to develop COVID-19 vaccine candidate MarketWatch +16.04%
Mar-16-20 08:00AM  Heat Biologics Invited to Join The Alliance for Biosecurity ACCESSWIRE +10.64%
Mar-11-20 09:23AM  Biotech Maven Hal Mintz Snaps Up These 3 Small Biotech Stocks TipRanks +16.65%
Mar-09-20 10:55AM  On the Back of Possible Coronavirus Vaccine, Analyst Sees Over 170% Upside for Heat Biologics TipRanks +5.31%
Mar-06-20 01:52PM  TBJ Plus: Coronavirus threatens ACC Tournament, hurts Raleigh restaurants; Reynolds mansion still unsold; Peek inside this new brewery American City Business Journals -15.52%
Mar-05-20 04:45PM  Heat Biologics, Inc. to Present at the Spring Investor Summit on March 25th-26th in New York City ACCESSWIRE +18.29%
09:00AM  Heat Biologics Announces Research Collaboration with University of Miami to Develop Vaccine Designed to Protect Against COVID-19 Coronavirus ACCESSWIRE
Mar-04-20 03:10PM  Heat Biologics CEO to Appear Today on ABC11-WTVD to Discuss the Companys Newly Launched Program to Develop a Vaccine to Protect Against SARS-CoV-2 Coronavirus that Causes COVID-19 ACCESSWIRE +35.92%
09:48AM  3 Biotech Stocks Join the Coronavirus Fight TipRanks
Mar-03-20 02:41PM  Morrisville company joins race for coronavirus vaccine American City Business Journals -24.59%
08:00AM  Benzinga Pro's Top 6 Stocks To Watch For Tues., Mar. 3, 2020: TGT, BYND, UBER, NOVN, QRVO, HTBX Benzinga
08:00AM  Heat Biologics Launches Program to Develop Vaccine Designed to Protect Against COVID-19 Coronavirus ACCESSWIRE
Feb-28-20 02:15PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Heat Biologics, Inc.- HTBX ACCESSWIRE +54.93%
Feb-24-20 02:59PM  Advance Auto Parts, Cree among Triangle companies hit as stocks tumble with rising concern over coronavirus American City Business Journals
Jan-21-20 04:05PM  Heat Biologics, Inc. Announces Closing of $7,000,000 Public Offering ACCESSWIRE
Jan-16-20 09:50AM  Heat Biologics, Inc. Prices $7,000,000 Public Offering ACCESSWIRE -24.36%
Jan-15-20 02:33PM  Triangle drugmaker preps for public offering American City Business Journals
Dec-23-19 08:39AM  Here's What We Think About Heat Biologics, Inc.'s (NASDAQ:HTBX) CEO Pay Simply Wall St.
Dec-16-19 07:00AM  Heat Biologics Announces First Patient Dosed in the First Phase 1 Trial of HS-130 ACCESSWIRE
Nov-29-19 05:05AM  HTBX: Third Quarter 2019 Results Zacks Small Cap Research
Nov-20-19 08:00AM  Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients ACCESSWIRE -10.21%
Nov-19-19 07:56AM  The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout Benzinga +21.84%
Nov-18-19 08:00AM  Heat Biologics Announces Additional Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients at AACR Tumor Immunology and Immunotherapy Conference ACCESSWIRE
Nov-15-19 08:30AM  Heat Biologics Reports Third Quarter 2019 Results and Provides Corporate Update ACCESSWIRE
Nov-11-19 07:00AM  Heat Biologics Presents Additional Phase 2 Interim Data in Advanced NSCLC Patients at the SITC 34th Annual Meeting ACCESSWIRE -8.69%
Nov-08-19 08:14AM  The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut Benzinga
Nov-07-19 08:02AM  We Think Heat Biologics (NASDAQ:HTBX) Needs To Drive Business Growth Carefully Simply Wall St. -8.18%
Nov-05-19 08:00AM  Heat Biologics Reports Positive Phase 2 Interim Data in NSCLC Patients Who Previously Failed Checkpoint Inhibitor Treatment ACCESSWIRE -13.13%
Oct-24-19 09:00AM  Heat Biologics Announces a Poster Presentation of Updated Top Line Phase 2 Data of HS-110 plus Nivolumab after Checkpoint Inhibitor Treatment Failure in NSCLC Patients at the SITC 34th Annual Meeting ACCESSWIRE +8.99%
Oct-02-19 09:23AM  What Kind Of Shareholders Own Heat Biologics, Inc. (NASDAQ:HTBX)? Simply Wall St.
Aug-27-19 08:44AM  Introducing Heat Biologics (NASDAQ:HTBX), The Stock That Collapsed 99% Simply Wall St.
Aug-26-19 12:30PM  HTBX: HS-130 Ready To Go Zacks Small Cap Research
Aug-24-19 01:46PM  10 Biopharmaceutical Companies Trying To Cure Cancer Benzinga
Aug-14-19 07:00AM  Heat Biologics Reports Second Quarter 2019 Results and Provides Corporate Update ACCESSWIRE -6.57%
Aug-12-19 07:00AM  Heat Biologics Announces FDA Clearance of IND Application to Begin Phase 1 Trial of HS-130 in Combination with Heats HS-110 ACCESSWIRE
Aug-07-19 11:15AM  Heat Biologics CEO and Lead Director to Participate in German Investor Forums ACCESSWIRE -7.46%
Jul-10-19 02:41PM  What You Must Know About Heat Biologics, Inc.'s (NASDAQ:HTBX) Beta Value Simply Wall St.
Jul-09-19 08:00AM  Heat Biologics Completes Enrollment in Phase 2 Non-Small Cell Lung Cancer Trial ACCESSWIRE
Jun-12-19 01:30PM  HTBX: INDs To Be Filed Soon Zacks Small Cap Research
Jun-03-19 06:55AM  Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure ACCESSWIRE +7.89%
May-23-19 11:09AM  Is Heat Biologics, Inc.'s (NASDAQ:HTBX) CEO Overpaid Relative To Its Peers? Simply Wall St. -12.52%
May-20-19 08:30AM  Heat Biologics to Present at the 20th Annual B. Riley FBR Institutional Investor Conference ACCESSWIRE -5.22%
May-15-19 07:30AM  Heat Biologics Reports First Quarter 2019 Results and Provides Corporate Update ACCESSWIRE
May-06-19 07:00AM  Heat Biologics Lead Director to Present at the ChinaBio 2019 Conference in Shanghai ACCESSWIRE
Apr-18-19 05:30PM  Heat Biologics CEO to Present at the ThinkEquity Conference in New York City ACCESSWIRE
Apr-11-19 09:30AM  HTBX: 2018 Financial & Operational Results Zacks Small Cap Research
Apr-02-19 08:00AM  Heat Biologics Delivers Poster Presentation at the AACR Annual Meeting 2019 ACCESSWIRE
Mar-28-19 07:30AM  Heat Biologics Reports 2018 Results and Provides Corporate Update ACCESSWIRE
Mar-21-19 07:00AM  Heat Biologics to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy ACCESSWIRE
Mar-11-19 10:40AM  HTBX: HS-110 Interim Update Zacks Small Cap Research
Mar-05-19 09:25AM  Heat Biologics Lead Director to Chair Oncology Roundtable Discussion at WuXi Healthcare Forum in Shanghai ACCESSWIRE -6.02%
Feb-28-19 05:00PM  Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium ACCESSWIRE
Feb-26-19 09:45AM  These Four Healthcare Stocks Are Heating Up On Tuesday ACCESSWIRE +17.04%
Feb-13-19 10:03AM  What Type Of Shareholder Owns Heat Biologics, Inc.s (NASDAQ:HTBX)? Simply Wall St.
Jan-14-19 02:15PM  UPDATE: Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial ACCESSWIRE +16.80%
08:00AM  Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial ACCESSWIRE
Jan-10-19 08:27AM  The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits Benzinga
06:30AM  Heat Biologics Provides Clinical and Business Update ACCESSWIRE
Jan-08-19 06:30AM  Heat Biologics Principal Investigator Selected to Deliver Oral Presentation of New HS-110 Interim Phase 2 Data at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium ACCESSWIRE
Jan-04-19 07:00AM  Heat Biologics to Present at Biotech Showcase 2019 in California ACCESSWIRE
Dec-03-18 10:15AM  HTBX: Plenty of Catalysts in 2019 Zacks Small Cap Research
Nov-27-18 08:38AM  Durham company rakes in another $13.8M through public offering American City Business Journals
Nov-26-18 04:00PM  Heat Biologics, Inc. Announces Closing of $13,800,000 Public Offering ACCESSWIRE
06:00AM  Heat Biologics to Participate in Panel Presentation at the Goldman Sachs Asia Pacific Healthcare Forum ACCESSWIRE
Nov-23-18 08:15AM  Detailed Research: Economic Perspectives on Whirlpool, GrafTech International, Thermon Group, White Mountains Insurance Group, Air Industries Group, and Heat Biologics What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-21-18 03:21PM  Heat Biologics Takes Beating After Pricing $12 Million Stock Offering TheStreet.com -30.73%
01:37PM  Should You Be Concerned About Heat Biologics Incs (NASDAQ:HTBX) Historical Volatility? Simply Wall St.
08:04AM  The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO Benzinga
07:30AM  Heat Biologics, Inc. Prices $12,000,000 Public Offering ACCESSWIRE
Nov-20-18 03:10PM  Heat Biologics, Inc. Announces Proposed Public Offering ACCESSWIRE +9.04%
Nov-15-18 07:00AM  Heat Biologics Reports Third Quarter 2018 Results and Provides Corporate Update ACCESSWIRE +8.55%
Oct-22-18 07:00AM  Heat Biologics to Present at Precision: Lung Cancer World R&D Summit ACCESSWIRE
Oct-19-18 07:00AM  Heat Biologics CEO to Participate in Panel Presentation at The Cellular ''Living Drug'' Revolution Summit in New York City ACCESSWIRE
Oct-10-18 07:00AM  Heat Biologics to Present at the 2018 BIO Investor Forum ACCESSWIRE -5.70%
Oct-04-18 07:00AM  Heat Biologics Pelican Subsidiary Provides Update on its Novel PTX-35 T-Cell Costimulator ACCESSWIRE
Sep-26-18 03:16PM  What does Heat Biologics Incs (NASDAQ:HTBX) Balance Sheet Tell Us About Its Future? Simply Wall St.
Aug-29-18 09:45AM  HTBX: Multiple Milestones on the Horizon Zacks Small Cap Research
07:00AM  Heat Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City ACCESSWIRE
Aug-15-18 04:21PM  Heat Biologics Stock Is a Worthwhile, Speculative Bet InvestorPlace
Aug-14-18 07:30AM  Heat Biologics Reports Second Quarter 2018 Results and Provides Corporate Update ACCESSWIRE
Jul-30-18 07:00AM  Stock Performance Review on Amicus Therapeutics and Three Other Biotech Stocks ACCESSWIRE
Jul-16-18 09:45AM  HTBX: Heat Biologics: Making an ImPACT on Cancer Zacks Small Cap Research
Jun-29-18 07:10AM  Anthera Pharma and Three Additional Stocks Under Scanner in the Biotech Space ACCESSWIRE
Jun-07-18 08:00AM  Today's Research Reports on Stocks to Watch: Axovant Sciences and Heat Biologics ACCESSWIRE
Jun-06-18 01:22PM  Is Heat Biologics Inc (NASDAQ:HTBX) Excessively Paying Its CEO? Simply Wall St. +22.13%
May-30-18 07:00AM  Heat Biologics to Present at the 2018 BIO International Convention ACCESSWIRE
May-25-18 07:15AM  Wired News - Clementia Announced Encouraging Phase-2 Part B Data Evaluating Palovarotene for FOP Treatment ACCESSWIRE
May-24-18 07:15AM  Complimentary Technical Snapshots on Heat Biologics and Three More Biotech Stocks ACCESSWIRE +6.80%
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer; and HS-130, which is in phase I clinical trials for the treatment of advanced solid tumors. The company's preclinical stage products include PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling, as well as develops COVID-19 vaccine program and diagnostic test. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.